CR UK, CRT Pioneer Fund and the NCI link on RAS
Cancer Research UK and the Cancer Research Technology Pioneer Fund are committing £2.5 million in collaboration with the US’ National Cancer Institute to tackle RAS, one of the most common driving mutations in aggressive, hard to treat cancers.
Read More
